Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Trimeris Shares Increase 13% as Sales of Fuzeon Rise in Europe, Brazil; Analysts Predict Profit as Early as 2006

July 22, 2005

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Shares of Durham, N.C.-based pharmaceutical company Trimeris on Wednesday rose by 13% -- closing at $12.75 per share, up $1.43 -- after the company reported second-quarter losses more favorable than analysts' predictions, the Raleigh News & Observer reports. Increases in sales of the company's antiretroviral drug Fuzeon in Europe and Brazil cut losses by 80% for the second quarter of 2005, and the company lost 14 cents per share, compared with a loss of 17 cents per share, as had been predicted by analysts at Thomson Financial. Sales of Fuzeon outside North America increased in the second quarter, accounting for more than half of the drug's $53.9 million in second-quarter sales. Analysts "believe things are beginning to look positive for Trimeris," Legg Mason analyst Edward Nash wrote in a research report following the release of the company's earnings report (Vollmer, Raleigh News & Observer, 7/21).

Back to other news for July 22, 2005


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More Research on T-20 (Enfuvirtide, Fuzeon)
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement